Endo International plc, a specialty pharmaceutical company, manufactures and sells generic and branded pharmaceuticals in the United States and internationally. Its Branded Pharmaceuticals segment provides branded prescription products, including XIAFLEX to treat adult patients with Dupuytren's contracture; SUPPRELIN LA to treat central precocious puberty in children; NASCOBAL nasal spray to treat vitamin B12 deficiency; AVEED to treat hypogonadism; QWO, an injectable treatment for moderate to severe cellulite in the buttocks of adult women; PERCOCET to treat moderate-to-moderately-severe pain; TESTOPEL an implantable pellet indicated for TRT in conditions associated with a deficiency or absence of endogenous testosterone; EDEX to treat erectile dysfunction; LIDODERM a topical patch product containing lidocaine for the relief of pain; and products for the pain management and urology. The company's Sterile Injectables segment manufactures VASOSTRICT, a vasopressin injection; ADRENALIN, a non-selective adrenergic agonist; and APLISOL, which is a sterile aqueous solution, as well as generic sterile injectable products, including ertapenem for injections and ephedrine sulfate injections. Its Generic Pharmaceuticals segment offers solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmic products, and sprays. The company's International Pharmaceuticals segment offers specialty pharmaceutical products in various therapeutic areas comprising attention deficit hyperactivity disorder, pain, women's health, oncology, and transplantation. The company sells its branded pharmaceuticals and generics to specialty physicians, retailers, clinics, government agencies, doctors, retail and specialty pharmacies, and specialty distributors. Endo International plc was founded in 1920 and is headquartered in Dublin, Ireland. On August 16, 2022, Endo International plc, along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
Show more...
CEO
Blaise Coleman
Employees
2931
Country
IE
ISIN
IE00BJ3V9050
WKN
000A1XE6M
Listings
0 Comments
Share your thoughts
FAQ
What is Endo International stock price today?▼
The current price of ENDPQ is $0 USD — it has increased by +0% in the past 24 hours. Watch Endo International stock price performance more closely on the chart.
What is Endo International stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Endo International stocks are traded under the ticker ENDPQ.
What is Endo International revenue for the last year?▼
Endo International revenue for the last year amounts to 2.01B USD.
What is Endo International net income for the last year?▼
ENDPQ net income for the last year is -2.45B USD.
How many employees does Endo International have?▼
As of April 01, 2026, the company has 2,931 employees.
In which sector is Endo International located?▼
Endo International operates in the Professional, Scientific, and Technical Services sector.
When did Endo International complete a stock split?▼
Endo International has not had any recent stock splits.
Where is Endo International headquartered?▼
Endo International is headquartered in Dublin, IE.